Company news
Mindwalk Holdings Corp. (NASDAQ:HYFT) news
Every Mindwalk Holdings Corp. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
July 23, 2026
MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure
July 22, 2026
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2026 on July 2...
July 13, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Added to the Russell 3000E Index, Expanding Institutional Investment Opportunity
July 6, 2026
MindWalk (NASDAQ: HYFT) CEO Dr. Jennifer Bath to Join Absci (NASDAQ: ABSI) and a Leading AI Compute Provider on Jones AI Day Panel on the...
June 12, 2026
MindWalk Holdings Corp. (NASDAQ: HYFT) Launches ReefIQ™, a Biological Context Layer for AI Drug Discovery
June 10, 2026
MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-R...
June 2, 2026
MindWalk Holdings Deploys Pandemic Response Platform via HYFT® Technology as Ebola and Hantavirus Outbreaks Expose the Limits of Strain-S...
May 27, 2026
The Biology Came First.
May 18, 2026
MindWalk Holdings Corp. Reports Q3 Fiscal 2026 Financial Results
March 12, 2026
MindWalk Announces B Cell Llama™, a Nanobody Discovery Platform Designed for the Bispecific and Cell Therapy Era
March 6, 2026
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026
March 2, 2026
MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics
January 27, 2026
MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease
January 14, 2026
REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
January 12, 2026
MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight
January 9, 2026
MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline
December 15, 2025
MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025
December 8, 2025
MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025
November 13, 2025
MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy
October 21, 2025
MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion
October 15, 2025
MindWalk Announces Share Repurchase Program
October 9, 2025
MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity
September 22, 2025
MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion...
September 15, 2025
MindWalk to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2026 on September 15, 2025
September 10, 2025
IPA’s Subsidiary, BioStrand, Provides an Update on LENSai™
October 25, 2023